Home
overview
Psychiatric disorders, most notably depression, are one of the largest growth areas in CNS medicine, representing an extremely lucrative market for the pharmaceutical industry. However, finding novel compounds offering significant advantages over what is already on the market for psychiatric disorders is not easy. With several key antidepressants and anti-anxiety drugs due to come off patent by 2008, pharmaceutical companies are searching for compounds with new modes of action, looking to find faster-acting therapies with fewer side effects and solutions for treatment-resistant patients.

This Conference will evaluate the progress in treatment of depression, anxiety, bipolar disorder and schizophrenia, providing cutting edge information on the most exciting compounds currently in the pipeline. The event will also include discussion on some of the difficulties of clinical development in this field and will assess how these challenges can be addressed. It will include a look at conducting proof of principal studies, clinical trial design, patient recruitment issues and combination treatments.

A unique opportunity to learn from leading industry experts including:
· Dr Amir Kalali, Global Scientific Head, CNS Therapeutics, Quintiles
· Dr Jeffrey Sprouse, Neuropharmacologist, Team Leader, Antidepressant Programme, Pfizer
· Dr Phil Skolnick, Senior Vice President, Research & Chief Scientific Officer, Dov Pharmaceuticals
· Dr Thomas Blackburn, Senior Director, Medical Affairs, H Lundbeck
· Professor Tonmoy Sharma, Director, Clinical Neuroscience Research Centre

The essential event on:
· TREATING PSYCHIATRIC DISORDERS: Evaluate current progress in the treatment and understanding of depression, anxiety, bipolar disorder and schizophrenia
· THE LATEST IN CLINICAL DEVELOPMENTS: Understand cutting edge information on the most exciting compounds currently in the pipeline
· CLINICAL CHALLENGES: Discover some of the difficulties of clinical developments and how these challenges can be overcome
· KEY INDUSTRY PERSONNEL: Meet the leaders in the field and learn from their experiences

"This was a very interesting, useful and relevant conference. I am really glad I was able to participate."
Dr Phil Skolnick, Vice President, Research & Chief Scientific Officer, Dov Pharmaceutical, SMi’s Depression & Anxiety Conference 2003

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Geoffrey Dunbar

Dr Geoffrey Dunbar, Vice President, Clinical Development & Regulatory Affairs, Targacept

9:10 BIOMONITORING IN DRUG DISCOVERY RESEARCH FOR AFFECTIVE SPECTRUM DISORDERS

Dr Pim Drinkenburg

Dr Pim Drinkenburg, Principle Scientist & Head, Biomonitoring Research, Johnson & Johnson

  • Prediction of clinical efficacy: usefulness of EEG and in vivo microdialysis studies
  • Bridging preclinical and clinical psychiatric drug discovery research
  • Sleep-wake studies and circadian in antidepressant treatments
  • 9:40 PSYCHIATRIC CLINICAL TRIAL DESIGN

    Dr Amir Kalali

    Dr Amir Kalali, Global Scientific Head, CNS Therapeutics, Quintiles

  • Challenges in clinical development
  • Possible ways to reduce the risk of failure
  • 10:20 SIGNAL DETECTION IN CLINICAL TRIALS

    Dr Craig Mallinckrodt

    Dr Craig Mallinckrodt, Eli Lilly,

  • Lessons to be learnt from previous clinical trials
  • Variability of placebo response, lack of value of single blind ‘lead in’ periods and the effect of severity at entry revealing pertinent insights into the success of clinical trials
  • Prospective efforts to better understand placebo response
  • Enlarging and sharing relevant databases across centres and companies
  • Government, industries and academic collaborations to evaluate novel antidepressants
  • 11:00 Morning Coffee

    11:20 PANEL DISCUSSION

    Dr Jeffrey Sprouse

    Dr Jeffrey Sprouse, Associate Research Fellow, Pfizer

    Dr Thomas Blackburn

    Dr Thomas Blackburn, Senior Director, Medical Affairs, H Lundbeck

    Dr Cesare Mondadori

    Dr Cesare Mondadori, Chief Scientific Officer, Neuro3d

    Dr Paolo Bettica

    Dr Paolo Bettica, Director, Clinical Pharmacology & Discovery Medicine, Psychiatry CEDD, GlaxoSmithKline

    Professor Hermann Fuder

    Professor Hermann Fuder, Vice President & Principal Consultant, Clinical Pharmacology, Parexel

    12:00 CHARACTERISING AND TREATING TREATMENT RESISTANCE DEPRESSION

    Prof Tonmoy Sharma

    Prof Tonmoy Sharma, Director, Clinical Neuroscience Research Centre
    View Bio

  • Associated problems: under-recognition of the deficits
  • The cognitive deficits in depression
  • State vs trait
  • Current tools to accurately characterise cognitive dysfunction
  • Therapeutic options for the treatment of depression including Monotherapy, Electroconvulsive Therapy (ECT), psychotherapy, combination strategies and augmentation strategies
  • New approaches: antipsychotic drugs and treatment resistance
    Novel antipsychotics and their effects on treatment resistant depression including cognitive deficits
  • 12:40 Networking Lunch

    14:00 DEVELOPMENT OF FIXED DOSE COMBINATIONS IN DEPRESSION AND ANXIETY

    Dr Paolo Bettica

    Dr Paolo Bettica, Director, Clinical Pharmacology & Discovery Medicine, Psychiatry CEDD, GlaxoSmithKline

  • Advantages and limitations of the current antidepressants and anxiolytics
  • Potential improvements of new antidepressants and anxiolytics in development
  • Should we develop a fixed dose combination for the treatment of depression and anxiety?
  • Regulatory implications in the development of a fixed dose combination for depression and anxiety
  • 14:40 BIPOLAR DISORDER

    Dr Charles Large

    Dr Charles Large, Head, Electrophysiology, GlaxoSmithKline

  • Current methods of diagnosis
  • Epidemiology of bipolar disorder
  • Classification of bipolar disorder: the choice of biological treatment
  • Clinical states and course specifiers: implications for treatment
  • Future mood stabilising and superior antidepressant properties
  • The long term management of bipolar disorder
    Lamictal sodium channel inhibitor bipolar disorder: a case study
  • 15:20 NOVEL CONCEPTS OF SCHIZOPHRENIA TREATMENTS

    Prof Hermann Fuder

    Prof Hermann Fuder, President & Principal Consultant Clinical Pharmacology, Parexel

  • Unmet needs in the treatment of schizophrenics
  • Profile of typical and atypical antipsychotics
  • Positive, negative symptoms vs cognition
  • Treatment with glycine
  • Glycine uptake inhibition
  • 16:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Hermann Fuder

    Prof Hermann Fuder, President & Principal Consultant Clinical Pharmacology, Parexel

    9:10 GABAA RECEPTOR SUBTYPE-SELECTIVE MODULATORS

    Dr John Atack

    Dr John Atack, Senior Investigator, Merck Sharp & Dohme

  • Generalised Anxiety Disorder (GAD) – the nature of the problem
  • Current treatments for GAD and their limitations
  • Benzodiazepines and GABBAA receptors
  • Which GABAA subtypes are associated with anxiety?
  • Characteristics of a GABAA subtype-selective non-sedating anxiolytic
  • 9:40 SCHIZOPHRENIA: SELECTING THE RIGHT PHARMACOLOGICAL TARGET

    Dr Cesare Mondadori

    Dr Cesare Mondadori, Chief Scientific Officer, Neuro3d

  • New targets, hopes and reality
  • Drug discovery in small companies
  • Can we learn from history
  • Outlook
  • 10:20 CLINICAL DEVELOPMENT OF ANTIDEPRESSANTS

    Dr Rico Nil

    Dr Rico Nil, Regional Medical Director, H Lundbeck

  • Depression: diagnostics issues
  • Treatment of depression
  • Unmet needs
  • The placebo problem
  • Guidelines
  • The clinical development plan
  • 11:00 Morning Coffee

    11:20 SEROTONIN AUTORECEPTOR ANTAGONISTS IN DEPRESSION

    Dr Jeffrey Sprouse

    Dr Jeffrey Sprouse, Associate Research Fellow, Pfizer

  • The development of 5-HT1B antagonists: proof of concept data from the laboratory
  • Potential advantages due to the blockade of autoreceptors and hetoreceptors that modulate transmitter release
  • A drug discovery approach both unprecedented and precedented
  • Future prospects including combination therapies
  • 12:00 A TRIPLE UPTAKE INHIBITOR

    Dr Phil Skolnick

    Dr Phil Skolnick, Senior Vice President, Research & Chief Scientific Officer, DOV Pharmaceutical

  • Triple uptake inhibitor affecting the neurotransmitters norepinephrine, serotonin and dopamine
  • Preclinical promises: potently inhibiting the uptake of all three neurotransmitters
  • Fast acting-fast healing?
  • Safety, tolerability and PK profile
  • Looking towards phase II: multi-centred, doubleblind, safety, efficacy and tolerability clinical trial
  • Feasible comparisons to leading SSRI in patients with major depressive disorder?
  • 12:40 Networking Lunch

    14:40 NEUROPEPTIDES IN PSYCHIATRIC DISORDERS

    Dr Thomas Blackburn

    Dr Thomas Blackburn, Senior Director, Medical Affairs, H Lundbeck

  • Neuropeptides: attractive therapeutic targets for depression and anxiety disorders
  • The list of potential targets is ever increasing (NK1, CRF, vasopressin, MCH, NPY and galanin)
  • Clinical assessment of several compounds is currently underway and will be discussed
  • Where have we come from and what does the future hold?
  • 14:40 NEURODEGENERATION IN DEPRESSION

    Dr Roger Pinder

    Dr Roger Pinder, Vice President, Medical Affairs, CNS & Thrombosis, Organon International

  • HPA axis dysfunction in depression
  • Hippocampal changes in depression
  • Antidepressants and HPA axis function
  • Glucorticoid receptor antagonists as antidepressants
  • Reversal of hippocampal atrophy
  • 15:20 Afternoon Tea

    15:20 NEURONAL NICOTINIC RECEPTOR (NNR) MODULATION IN THE TREATMENT OF ANXIETY AND DEPRESSION

    Dr Geoffrey Dunbar

    Dr Geoffrey Dunbar, Vice President, Clinical Development & Regulatory Affairs, Targacept

  • Present anti-depressant and anti-anxiety treatments are inadequate
  • The NNR agonist nicotine has a long history of use in treating symptoms of anxiety and depression
  • Older molecules have failed in the clinic because of peripheral side effects
  • Present generation of compounds are CNS selective and offer a possible new therapeutic approach
  • Increased speed of onset of action is a real possibility
  • 16:00 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.